What Steris's 8-K filings say: 4 filings, latest Oct 13, 2026
Steris filed its latest 8-K with the SEC on Oct 13, 2026. It discusses acquisition announced and debt refinancing.
Public (STE)Medical Equipment Manufacturing10,000+ employeessteris.comLinkedIn
Get Steris' live signals in Claude or ChatGPT, or by API
What changed at Steris this week? Use Autobound signals for steris.com.- Filed
- Oct 13, 2026
- Filings
- 4
- Signals
- 11
Source: Autobound Signal API · 90 signals tracked for Steris · updated
8-K · latest 6
What Steris's 8-K filings say
- SEC EDGAR
8-K
Filed · 2 signals
STERIS to acquire Xodus Medical for $2.1 billion in cash plus potential earnout
$2.1B
cash purchase price at closing to acquire Xodus Medical
JPMorgan Chase Bank, N.A.Goldman Sachs Bank USA
STERIS Secures Up to $2.0 Billion Senior Unsecured Bridge Facility for Xodus Medical Acquisition
STERIS entered into a bridge financing commitment with JPMorgan and Goldman Sachs for up to $2.0 billion to finance its $2.1 billion acquisition of Xodus Medical.
$2B
senior unsecured bridge facility commitment
JPMorgan Chase Bank, N.A.Goldman Sachs Bank USA
- SEC EDGAR
8-K
Filed · 3 signals
- SEC EDGAR
8-K
Filed · 3 signals
STERIS announces $55M-$70M manufacturing consolidation and restructuring plan
STERIS is closing manufacturing and distribution facilities in Missouri and Minnesota to consolidate into a new Center of Excellence in North Carolina.
$55M
Minimum expected pre-tax restructuring charges for manufacturing consolidation plan (range is $55M-$70M)
STERIS announces $55-70M consolidation plan, closing facilities in Missouri and Minnesota.
The company is closing two manufacturing and distribution facilities and building a new Center of Excellence in North Carolina.
$70M
Maximum expected total pre-tax restructuring charges for facility consolidation plan.
- SEC EDGAR
8-K
Filed · 3 signals
STERIS appoints bioMérieux CEO Pierre Boulud to its Board of Directors, effective May 5, 2026.
The appointment of a new director, who is the current CEO of a diagnostics-focused biotech company, may signal a shift in strategic priorities or an increased focus on in vitro diagnostics.
$0.1M
Prorated fee for new director Pierre Boulud for the remainder of the Board’s 2025-26 term of office.
in vitro diagnosticsBoston Consulting Group
Showing 6 of 11 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Steris with the Signal API
One POST /v1/companies/enrich call with steris.com returns Steris 8-K signals (sec-8k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"steris.com","signal_types":["sec-8k"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 8-K Filings records, as a CSV.
Same industry
8-K at related companies
Questions about Steris 8-K
When did Steris file its latest 8-K?
What did Steris disclose in its latest 8-K?
Where can I read Steris's 8-K filing?
Page updated , the date of the newest row on this page.
Source. Current reports (Form 8-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .